vs
渤健（BIIB）与Jacobs Solutions（J）财务数据对比。点击上方公司名可切换其他公司
Jacobs Solutions的季度营收约是渤健的1.4倍（$3.3B vs $2.3B），Jacobs Solutions净利率更高（3.8% vs -2.1%，领先6.0%），Jacobs Solutions同比增速更快（12.3% vs -7.1%），渤健自由现金流更多（$468.0M vs $364.9M），过去两年渤健的营收复合增速更高（-0.2% vs -12.2%）
渤健是总部位于美国马萨诸塞州剑桥市的跨国生物技术企业，专注于神经系统疾病治疗领域。公司核心产品包括用于多发性硬化症的特菲达、万立能等多款药物，以及治疗脊髓性肌萎缩症的诺西那生钠、治疗弗里德赖希共济失调的Skyclarys，致力于为神经疾病和罕见病患者提供创新疗法。
Jacobs Solutions是总部位于美国得克萨斯州达拉斯市的国际技术专业服务企业，面向全球各类企业、社会组织及政府机构客户，提供工程、技术、专业及施工服务，同时开展科学研究与专项咨询业务，在所属行业长期处于领先地位。
BIIB vs J — 直观对比
营收规模更大
J
是对方的1.4倍
$2.3B
营收增速更快
J
高出19.4%
-7.1%
净利率更高
J
高出6.0%
-2.1%
自由现金流更多
BIIB
多$103.1M
$364.9M
两年增速更快
BIIB
近两年复合增速
-12.2%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $2.3B | $3.3B |
| 净利润 | $-48.9M | $125.5M |
| 毛利率 | 78.3% | 23.2% |
| 营业利润率 | -2.5% | 7.1% |
| 净利率 | -2.1% | 3.8% |
| 营收同比 | -7.1% | 12.3% |
| 净利润同比 | -118.3% | 792.3% |
| 每股收益（稀释后） | $-0.35 | $1.12 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BIIBJ
| Q4 25 | $2.3B | $3.3B | ||
| Q3 25 | $2.5B | $3.2B | ||
| Q2 25 | $2.6B | $3.0B | ||
| Q1 25 | $2.4B | $2.9B | ||
| Q4 24 | $2.5B | $2.9B | ||
| Q3 24 | $2.5B | $-1.2B | ||
| Q2 24 | $2.5B | $4.2B | ||
| Q1 24 | $2.3B | $4.3B |
净利润BIIBJ
| Q4 25 | $-48.9M | $125.5M | ||
| Q3 25 | $466.5M | $122.2M | ||
| Q2 25 | $634.8M | $179.6M | ||
| Q1 25 | $240.5M | $5.6M | ||
| Q4 24 | $266.7M | $-18.1M | ||
| Q3 24 | $388.5M | $325.4M | ||
| Q2 24 | $583.6M | $146.9M | ||
| Q1 24 | $393.4M | $162.1M |
毛利率BIIBJ
| Q4 25 | 78.3% | 23.2% | ||
| Q3 25 | 73.4% | 24.3% | ||
| Q2 25 | 77.1% | 25.0% | ||
| Q1 25 | 74.1% | 25.4% | ||
| Q4 24 | 76.2% | 24.6% | ||
| Q3 24 | 74.1% | — | ||
| Q2 24 | 77.8% | 21.7% | ||
| Q1 24 | 76.3% | 21.2% |
营业利润率BIIBJ
| Q4 25 | -2.5% | 7.1% | ||
| Q3 25 | 22.0% | 6.7% | ||
| Q2 25 | 28.1% | 7.8% | ||
| Q1 25 | 12.8% | 7.2% | ||
| Q4 24 | 11.9% | 7.1% | ||
| Q3 24 | 18.3% | — | ||
| Q2 24 | 28.3% | 6.2% | ||
| Q1 24 | 20.3% | 6.6% |
净利率BIIBJ
| Q4 25 | -2.1% | 3.8% | ||
| Q3 25 | 18.4% | 3.9% | ||
| Q2 25 | 24.0% | 5.9% | ||
| Q1 25 | 9.9% | 0.2% | ||
| Q4 24 | 10.9% | -0.6% | ||
| Q3 24 | 15.8% | -28.1% | ||
| Q2 24 | 23.7% | 3.5% | ||
| Q1 24 | 17.2% | 3.8% |
每股收益（稀释后）BIIBJ
| Q4 25 | $-0.35 | $1.12 | ||
| Q3 25 | $3.17 | $0.88 | ||
| Q2 25 | $4.33 | $1.55 | ||
| Q1 25 | $1.64 | $0.06 | ||
| Q4 24 | $1.82 | $-0.11 | ||
| Q3 24 | $2.66 | $2.50 | ||
| Q2 24 | $4.00 | $1.17 | ||
| Q1 24 | $2.70 | $1.28 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $1.6B |
| 总债务越低越好 | $6.3B | — |
| 股东权益账面价值 | $18.3B | $3.4B |
| 总资产 | $29.4B | $11.6B |
| 负债/权益比越低杠杆越低 | 0.34× | — |
8季度趋势，按日历期对齐
现金及短期投资BIIBJ
| Q4 25 | — | $1.6B | ||
| Q3 25 | — | $1.2B | ||
| Q2 25 | — | $1.3B | ||
| Q1 25 | — | $1.2B | ||
| Q4 24 | — | $1.3B | ||
| Q3 24 | — | $1.1B | ||
| Q2 24 | — | $1.2B | ||
| Q1 24 | — | $1.0B |
总债务BIIBJ
| Q4 25 | $6.3B | — | ||
| Q3 25 | $6.3B | — | ||
| Q2 25 | $6.3B | — | ||
| Q1 25 | $4.5B | — | ||
| Q4 24 | $6.3B | — | ||
| Q3 24 | $4.5B | — | ||
| Q2 24 | $6.3B | — | ||
| Q1 24 | $6.3B | — |
股东权益BIIBJ
| Q4 25 | $18.3B | $3.4B | ||
| Q3 25 | $18.2B | $3.6B | ||
| Q2 25 | $17.6B | $3.8B | ||
| Q1 25 | $17.0B | $3.9B | ||
| Q4 24 | $16.7B | $4.2B | ||
| Q3 24 | $16.4B | $4.5B | ||
| Q2 24 | $15.9B | $6.6B | ||
| Q1 24 | $15.2B | $6.6B |
总资产BIIBJ
| Q4 25 | $29.4B | $11.6B | ||
| Q3 25 | $29.2B | $11.3B | ||
| Q2 25 | $28.3B | $11.4B | ||
| Q1 25 | $28.0B | $11.2B | ||
| Q4 24 | $28.0B | $11.6B | ||
| Q3 24 | $28.3B | $11.8B | ||
| Q2 24 | $26.8B | $15.0B | ||
| Q1 24 | $26.6B | $14.9B |
负债/权益比BIIBJ
| Q4 25 | 0.34× | — | ||
| Q3 25 | 0.35× | — | ||
| Q2 25 | 0.36× | — | ||
| Q1 25 | 0.27× | — | ||
| Q4 24 | 0.38× | — | ||
| Q3 24 | 0.28× | — | ||
| Q2 24 | 0.40× | — | ||
| Q1 24 | 0.41× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $511.9M | $380.8M |
| 自由现金流经营现金流 - 资本支出 | $468.0M | $364.9M |
| 自由现金流率自由现金流/营收 | 20.5% | 11.1% |
| 资本支出强度资本支出/营收 | 1.9% | 0.5% |
| 现金转化率经营现金流/净利润 | — | 3.03× |
| 过去12个月自由现金流最近4个季度 | $2.1B | $875.3M |
8季度趋势，按日历期对齐
经营现金流BIIBJ
| Q4 25 | $511.9M | $380.8M | ||
| Q3 25 | $1.3B | $383.1M | ||
| Q2 25 | $160.9M | $292.6M | ||
| Q1 25 | $259.3M | $-96.4M | ||
| Q4 24 | $760.9M | $107.5M | ||
| Q3 24 | $935.6M | $196.5M | ||
| Q2 24 | $625.8M | $482.6M | ||
| Q1 24 | $553.2M | $-42.8M |
自由现金流BIIBJ
| Q4 25 | $468.0M | $364.9M | ||
| Q3 25 | $1.2B | $353.5M | ||
| Q2 25 | $134.3M | $270.5M | ||
| Q1 25 | $222.2M | $-113.7M | ||
| Q4 24 | $721.6M | $97.1M | ||
| Q3 24 | $900.6M | $158.2M | ||
| Q2 24 | $592.3M | $444.9M | ||
| Q1 24 | $507.3M | $-70.6M |
自由现金流率BIIBJ
| Q4 25 | 20.5% | 11.1% | ||
| Q3 25 | 48.4% | 11.2% | ||
| Q2 25 | 5.1% | 8.9% | ||
| Q1 25 | 9.1% | -3.9% | ||
| Q4 24 | 29.4% | 3.3% | ||
| Q3 24 | 36.5% | -13.6% | ||
| Q2 24 | 24.0% | 10.5% | ||
| Q1 24 | 22.1% | -1.7% |
资本支出强度BIIBJ
| Q4 25 | 1.9% | 0.5% | ||
| Q3 25 | 1.8% | 0.9% | ||
| Q2 25 | 1.0% | 0.7% | ||
| Q1 25 | 1.5% | 0.6% | ||
| Q4 24 | 1.6% | 0.4% | ||
| Q3 24 | 1.4% | -3.3% | ||
| Q2 24 | 1.4% | 0.9% | ||
| Q1 24 | 2.0% | 0.7% |
现金转化率BIIBJ
| Q4 25 | — | 3.03× | ||
| Q3 25 | 2.73× | 3.13× | ||
| Q2 25 | 0.25× | 1.63× | ||
| Q1 25 | 1.08× | -17.18× | ||
| Q4 24 | 2.85× | — | ||
| Q3 24 | 2.41× | 0.60× | ||
| Q2 24 | 1.07× | 3.28× | ||
| Q1 24 | 1.41× | -0.26× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BIIB
| Products | $1.7B | 73% |
| Tysabri Product | $244.5M | 11% |
| AVONEX | $119.2M | 5% |
| SKYCLARYS | $88.9M | 4% |
| Alzheimers Collaboration | $47.1M | 2% |
| IMRALDI | $43.5M | 2% |
| TECFIDERA | $36.9M | 2% |
| PLEGRIDY | $24.7M | 1% |
| QALSODY | $7.8M | 0% |
| BYOOVIZ | $4.3M | 0% |
J
| Infrastructure Advanced Facilities | $2.9B | 89% |
| PA Consulting | $354.4M | 11% |
